Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics Inc. (MCRB)
:MCRB
Total Valuation
Seres Therapeutics has a market cap or net worth of $169.40M. The enterprise value is $139.20M.
Market Cap$169.40M
Enterprise Value$139.20M
Share Statistics
Seres Therapeutics has 8,754,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,754,570
Owned by Insiders3.32%
Owned by Institutions13.70%
Financial Efficiency
Seres Therapeutics’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -104.64%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)-104.64%
Return on Capital Employed (ROCE)-1.23
Revenue Per Employee0.00
Profits Per Employee1.32K
Employee Count103
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Seres Therapeutics is ―. Seres Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value187.37
Price to FCF―
Price to Operating Cash Flow-2.67
PEG Ratio―
Income Statement
In the last 12 months, Seres Therapeutics had revenue of 0.00 and earned 136.00K in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit-14.70M
Operating Income-121.31M
Pretax Income-125.77M
Net Income136.00K
EBITDA-111.07M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -59.94M and capital expenditures -434.00K, giving a free cash flow of -60.38M billion.
Operating Cash Flow-59.94M
Free Cash Flow-60.38M
Free Cash Flow per Share-6.90
Dividends & Yields
Seres Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.55
52-Week Price Change22.47%
50-Day Moving Average13.30
200-Day Moving Average13.43
Relative Strength Index (RSI)68.48
Average Volume (3m)127.84K
Important Dates
Seres Therapeutics upcoming earnings date is Nov 18, 2025, Before Open (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Seres Therapeutics as a current ratio of 0.94, with Debt / Equity ratio of 265.35%
Current Ratio0.94
Quick Ratio0.94
Debt to Market Cap0.04
Net Debt to EBITDA-0.55
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Seres Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Seres Therapeutics EV to EBITDA ratio is -23.80, with an EV/FCF ratio of -17.74.
EV to Sales0.00
EV to EBITDA-23.80
EV to Free Cash Flow-17.74
EV to Operating Cash Flow-17.79
Balance Sheet
Seres Therapeutics has $45.38M in cash and marketable securities with $87.43M in debt, giving a net cash position of $42.05M billion.
Cash & Marketable Securities$45.38M
Total Debt$87.43M
Net Cash$42.05M
Net Cash Per Share$4.80
Tangible Book Value Per Share$0.09
Margins
Gross margin is -50.54%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-50.54%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Seres Therapeutics is $14.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$14.00
Price Target Upside-27.65% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-100.00%
EPS Growth Forecast66.57%